Stockreport

Hungary Approves Trial Expansion as HT-001 Meets Primary Endpoint in Interim Analysis with Patients Reaching ARIGA =1 by Week Six [TheStreet.com]

Hoth Therapeutics, Inc.  (HOTH) 
PDF Over 65% of Patients Reported Reduced Pain and Itching; Zero Disruptions to EGFR Cancer Therapy with ~99% Lower Systemic Exposure NEW YORK April 1, 2026 /PRNewswire/ [Read more]